537 related articles for article (PubMed ID: 36494221)
41. Addressing controversial areas in the management of advanced prostate cancer in Canada Areas of consensus and controversy from the third Canadian consensus forum.
Saad F; Hotte SJ; Noonan K; Malone S; Morash C; Niazi T; Rendon RA; Shayegan B; Basappa NS; Cagiannos I; Danielson B; Delouya G; Fernandes R; Ferrario C; Finelli A; Gotto GT; Hamilton RJ; Izard JP; Kapoor A; Lalani AK; Lavallée LT; Ong M; Pouliot F; So AI; Yip S; Chi KN
Can Urol Assoc J; 2024 Apr; 18(4):E127-E137. PubMed ID: 38381937
[TBL] [Abstract][Full Text] [Related]
42. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.
Moris L; Cumberbatch MG; Van den Broeck T; Gandaglia G; Fossati N; Kelly B; Pal R; Briers E; Cornford P; De Santis M; Fanti S; Gillessen S; Grummet JP; Henry AM; Lam TBL; Lardas M; Liew M; Mason MD; Omar MI; Rouvière O; Schoots IG; Tilki D; van den Bergh RCN; van Der Kwast TH; van Der Poel HG; Willemse PM; Yuan CY; Konety B; Dorff T; Jain S; Mottet N; Wiegel T
Eur Urol; 2020 May; 77(5):614-627. PubMed ID: 32146018
[TBL] [Abstract][Full Text] [Related]
43. Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology.
Gómez-Caamaño A; González-San Segundo C; Henríquez I; Maldonado X; Zapatero A;
Clin Transl Oncol; 2019 Apr; 21(4):420-432. PubMed ID: 30293231
[TBL] [Abstract][Full Text] [Related]
44. Consensus on Prostate Cancer Treatment of Localized Disease With Very Low, Low, and Intermediate Risk: A Report From the First Prostate Cancer Consensus Conference for Developing Countries (PCCCDC).
Luz MA; Guimarães GC; Nardi AC; Pompeo ASFL; Sarkis ÁS; Nowier A; Lima Pompeo AC; Nardozza A; Adamy A; Carneiro A; Salvajoli BP; Benigno BS; Freitas CH; Chade CADC; Palhares DMF; Otero DAC; Neto DCVDS; Carvalhal EF; Gil E; Freire de Arruda F; Korkes F; Caserta Lemos G; Carvalhal GF; de Carvalho ÍT; Gimpel IFP; Chambô JL; Pontes J; Filho LAR; Nogueira LM; Wroclawski ML; Freitas MRP; Arap MA; Sadi MV; Bulbul M; Coelho RF; Gadia R; Khauli RB; Dos Reis RB; Rojas RAL; Guimarães RG; Aldousari S; Ferrigno R
JCO Glob Oncol; 2021 Apr; 7():523-529. PubMed ID: 33856894
[TBL] [Abstract][Full Text] [Related]
45. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; Van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Eur Urol; 2011 Apr; 59(4):572-83. PubMed ID: 21315502
[TBL] [Abstract][Full Text] [Related]
46. Managing Nonmetastatic Castration-resistant Prostate Cancer.
Mateo J; Fizazi K; Gillessen S; Heidenreich A; Perez-Lopez R; Oyen WJG; Shore N; Smith M; Sweeney C; Tombal B; Tomlins SA; de Bono JS
Eur Urol; 2019 Feb; 75(2):285-293. PubMed ID: 30119985
[TBL] [Abstract][Full Text] [Related]
47. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
48. Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus Meeting.
Mehra N; Kloots I; Vlaming M; Aluwini S; Dewulf E; Oprea-Lager DE; van der Poel H; Stoevelaar H; Yakar D; Bangma CH; Bekers E; van den Bergh R; Bergman AM; van den Berkmortel F; Boudewijns S; Dinjens WNM; Fütterer J; van der Hulle T; Jenster G; Kroeze LI; van Kruchten M; van Leenders G; van Leeuwen PJ; de Leng WWJ; van Moorselaar RJA; Noordzij W; Oldenburg RA; van Oort IM; Oving I; Schalken JA; Schoots IG; Schuuring E; Smeenk RJ; Vanneste BGL; Vegt E; Vis AN; de Vries K; Willemse PM; Wondergem M; Ausems M
Eur Urol Open Sci; 2023 Mar; 49():23-31. PubMed ID: 36874601
[TBL] [Abstract][Full Text] [Related]
49. Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus.
Desai C; Vaid AK; Biswas G; Batra S; Dattatreya PS; Mohapatra PN; Dabkara D; Gore A; Bhagat SB; Patil S; Barkate H
Oncol Ther; 2022 Jun; 10(1):143-165. PubMed ID: 35025089
[TBL] [Abstract][Full Text] [Related]
50. Adjuvant therapy for breast cancer.
NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
[TBL] [Abstract][Full Text] [Related]
51. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.
Fitzpatrick JM; Bellmunt J; Fizazi K; Heidenreich A; Sternberg CN; Tombal B; Alcaraz A; Bahl A; Bracarda S; Di Lorenzo G; Efstathiou E; Finn SP; Fosså S; Gillessen S; Kellokumpu-Lehtinen PL; Lecouvet FE; Oudard S; de Reijke TM; Robson CN; De Santis M; Seruga B; de Wit R
Eur J Cancer; 2014 Jun; 50(9):1617-27. PubMed ID: 24703899
[TBL] [Abstract][Full Text] [Related]
52. Current management of advanced and castration resistant prostate cancer.
Gomella LG; Petrylak DP; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
[TBL] [Abstract][Full Text] [Related]
53. "Non-metastatic, Castration-resistant Prostate Cancer: Diagnostic and Treatment Recommendations by an Expert Panel from Brazil".
Jardim DL; Gonçalves E Silva A; Pompeo ASFL; Sarkis AS; Cardoso APG; Sasse AD; Fay AP; Soares A; Pompeo ACL; Carneiro A; Kann AG; Fogassa C; De Freitas CH; Chade DC; Herchenhorn D; De Almeida DVP; Da Rosa DAR; Wiermann EG; Schutz FAB; Kater FR; De Moura F; Korkes F; Meyer F; De Oliveira FNG; Sabino F; Almeida GL; Avanço G; Guimaraes GC; Lemos GC; Carvalhal GF; Kim H; Morbeck IP; Campagnari JC; Rinck JA; Da Ponte JRT; Da Trindade KM; Atem L; Borges L; Nogueira LM; Batista LTEA; Maia MC; Sadi MV; Rocha MAA; Luz MA; Smaletz O; Lages PSM; Matuda RMK; Reis RBD; Indio RF; Fernandes RC; Cavallero SR; Souza VC; Busato W; Alfer W; Maluf F
Clin Genitourin Cancer; 2023 Apr; 21(2):e58-e69. PubMed ID: 36266221
[TBL] [Abstract][Full Text] [Related]
54. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.
Kumar S; Shelley M; Harrison C; Coles B; Wilt TJ; Mason MD
Cochrane Database Syst Rev; 2006 Oct; 2006(4):CD006019. PubMed ID: 17054269
[TBL] [Abstract][Full Text] [Related]
55. Evolving understanding and categorization of prostate cancer: preventing progression to metastatic castration-resistant prostate cancer: RADAR IV.
Crawford ED; Andriole G; Freedland SJ; Garnick M; Gomella LG; Henderson J; Higano CT; Kader AK; Kane C; Keane TE; Koo PJ; Petrylak DP; Reiter RE; Slovin SF; Yu EY
Can J Urol; 2020 Oct; 27(5):10352-10362. PubMed ID: 33049187
[TBL] [Abstract][Full Text] [Related]
56. Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1.
Crawford ED; Bryce AH; Hussain MH; Agarwal N; Beltran H; Cooperberg MR; Petrylak DP; Shore N; Spratt DE; Tagawa ST; Antonarakis ES; Aparicio AM; Armstrong AJ; Boike TP; Calais J; Carducci MA; Chapin BF; Cookson MS; Davis JW; Dorff T; Eggener SE; Feng FY; Gleave M; Higano C; Iagaru A; Morgans AK; Morris M; Murray KS; Poage W; Rettig MB; Sartor O; Scher HI; Sieber P; Small E; Srinivas S; Yu EY; Zhang T; Koo PJ
JU Open Plus; 2024 Apr; 2(4):. PubMed ID: 38774466
[TBL] [Abstract][Full Text] [Related]
57. NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
[TBL] [Abstract][Full Text] [Related]
58. Focal therapy in prostate cancer: international multidisciplinary consensus on trial design.
van den Bos W; Muller BG; Ahmed H; Bangma CH; Barret E; Crouzet S; Eggener SE; Gill IS; Joniau S; Kovacs G; Pahernik S; de la Rosette JJ; Rouvière O; Salomon G; Ward JF; Scardino PT
Eur Urol; 2014 Jun; 65(6):1078-83. PubMed ID: 24444476
[TBL] [Abstract][Full Text] [Related]
59. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent.
Cornford P; van den Bergh RCN; Briers E; Van den Broeck T; Brunckhorst O; Darraugh J; Eberli D; De Meerleer G; De Santis M; Farolfi A; Gandaglia G; Gillessen S; Grivas N; Henry AM; Lardas M; van Leenders GJLH; Liew M; Linares Espinos E; Oldenburg J; van Oort IM; Oprea-Lager DE; Ploussard G; Roberts MJ; Rouvière O; Schoots IG; Schouten N; Smith EJ; Stranne J; Wiegel T; Willemse PM; Tilki D
Eur Urol; 2024 Apr; ():. PubMed ID: 38614820
[TBL] [Abstract][Full Text] [Related]
60. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
